Real-world occurrence, therapy, and outcome of patients with class 2 or 3 BRAF compared with class 1 BRAF-mutated cancers
与 BRAF 突变 1 类癌症患者相比，BRAF 突变 2 类或 3 类癌症患者的真实世界发病率、治疗和预后
期刊:
影响因子:
doi:10.1016/j.esmorw.2024.100075
Pradervand, S; Freundler, N; Gosztonyi, B; Roncoroni, L; Achermann, R; Schwenk, T; de Fraipont, G; Garessus, J; Haefliger, S; Leichtle, A B; Kiessling, M K; Mueller-Focke, T; Krebs, F S; Zoete, V; Tsantoulis, P; Michielin, O; Britschgi, C; Wicki, A
